Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function

被引:99
作者
Schmidt, Shelley L. [1 ]
Tayob, Nabihah [2 ]
Han, Meilan K. [1 ]
Zappala, Christopher [3 ]
Kervitsky, Dolly [4 ]
Murray, Susan [2 ]
Wells, Athol U. [3 ]
Brown, Kevin K. [4 ]
Martinez, Fernando J. [1 ]
Flaherty, Kevin R. [1 ]
机构
[1] Univ Michigan Hlth Syst, Ann Arbor, MI USA
[2] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA
[3] Royal Brompton & Harefield Natl Hlth Serv Fdn Tru, London, England
[4] Natl Jewish Hlth, Denver, CO USA
基金
美国国家卫生研究院;
关键词
PLACEBO-CONTROLLED TRIAL; FORCED VITAL CAPACITY; PROGNOSTIC VALUE; PIRFENIDONE; SURVIVAL; DIAGNOSIS; BOSENTAN;
D O I
10.1378/chest.13-0844
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: The clinical course of idiopathic pulmonary fibrosis (IPF) is characterized by progressive decline in lung function and eventual mortality. We sought to determine if future declines in pulmonary function, mortality, or both can be predicted from prior trends in pulmonary function tests (PFTs). Methods: Data from 1981 to 2008 on 4,431 PFTs and mortality were analyzed from 734 subjects with IPF. The Kaplan-Meier method was used for mortality analyses. Mixed models were used to describe longitudinal pulmonary function dynamics, since PFTs were observed at varying time points from baseline. Results: During the first year of follow-up, 135 subjects (73%) had stable FVC while 50 subjects (37%) showed a decline in FVC. During months 12 to 24 (1-2 years after diagnosis), a stable FVC occurred with the same frequency among both subjects whose FVC had declined during year 1 and whose FVC had remained stable (84.0% and 80.7%, respectively; P = 5.59). Among subjects alive at the end of year 1, those with a stable FVC were more likely to be alive at the end of year 2 than those whose FVC declined (hazard ratio [HR], 0.91 [95% CI, 0.87-0.94] and HR, 0.71 [95% CI, 0.62-0.78], respectively). Conclusions: PFT decline predicts early mortality, but not future declines in physiology, regardless of time since diagnosis.
引用
收藏
页码:579 / 585
页数:7
相关论文
共 28 条
[1]  
Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646
[2]   Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis [J].
Azuma, A ;
Nukiwa, T ;
Tsuboi, E ;
Suga, M ;
Abe, S ;
Nakata, K ;
Taguchi, Y ;
Nagai, S ;
Itoh, H ;
Ohi, M ;
Sato, A ;
Kudoh, S ;
Raghu, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (09) :1040-1047
[3]   Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis [J].
Collard, HR ;
King, TE ;
Bartelson, BB ;
Vourlekis, JS ;
Schwarz, MI ;
Brown, KK .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (05) :538-542
[4]   High-dose acetylcysteine in idiopathic pulmonary fibrosis [J].
Demedts, M ;
Behr, J ;
Buhl, R ;
Costabel, U ;
Dekhuijzen, R ;
Jansen, HM ;
MacNee, W ;
Thomeer, M ;
Wallaert, B ;
Laurent, F ;
Nicholson, AG ;
Verbeken, EK ;
Verschakelen, J ;
Flower, CDR ;
Capron, F ;
Petruzzelli, S ;
De Vuyst, P ;
van den Bosch, JMM ;
Rodriguez-Becerra, E ;
Corvasce, G ;
Lankhorst, I ;
Sardina, M ;
Montanari, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21) :2229-2242
[5]   Idiopathic Pulmonary Fibrosis Lung Function Is a Clinically Meaningful Endpoint for Phase III Trials [J].
du Bois, Roland M. ;
Nathan, Steven D. ;
Richeldi, Luca ;
Schwarz, Marvin I. ;
Nobles, Paul W. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (08) :712-715
[6]   Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis Test Properties and Minimal Clinically Important Difference [J].
du Bois, Roland M. ;
Weycker, Derek ;
Albera, Carlo ;
Bradford, Williamson Z. ;
Costabel, Ulrich ;
Kartashov, Alex ;
King, Talmadge E., Jr. ;
Lancaster, Lisa ;
Noble, Paul W. ;
Sahn, Steven A. ;
Thomeer, Michiel ;
Valeyre, Dominique ;
Wells, Athol U. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (12) :1382-1389
[7]   Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis [J].
du Bois, Roland M. ;
Weycker, Derek ;
Albera, Carlo ;
Bradford, Williamson Z. ;
Costabel, Ulrich ;
Kartashov, Alex ;
Lancaster, Lisa ;
Noble, Paul W. ;
Raghu, Ganesh ;
Sahn, Steven A. ;
Szwarcberg, Javier ;
Thomeer, Michiel ;
Valeyre, Dominique ;
King, Talmadge E., Jr. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (04) :459-466
[8]  
du Bois RM, 2011, AM J RESP CRIT CARE, V183, P1231, DOI [10.1164/rccm.201007-1179OC, 10.1164/rccm.201007.1179OC]
[9]   The Prognostic Value of Cardiopulmonary Exercise Testing in Idiopathic Pulmonary Fibrosis [J].
Fell, Charlene D. ;
Liu, Lyrica Xiaohong ;
Motilka, Caroline ;
Kazerooni, Ella A. ;
Gross, Barry H. ;
Travis, William D. ;
Colby, Thomas V. ;
Murray, Susan ;
Toews, Galen B. ;
Martinez, Fernando J. ;
Flaherty, Kevin R. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179 (05) :402-407
[10]   Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia [J].
Flaherty, KR ;
Mumford, JA ;
Murray, S ;
Kazerooni, EA ;
Gross, BH ;
Colby, TV ;
Travis, WD ;
Flint, A ;
Toews, GB ;
Lynch, JP ;
Martinez, FJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (05) :543-548